Cargando…

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation

INTRODUCTION: IPX203 is a novel oral extended-release (ER) formulation of carbidopa (CD) and levodopa (LD) developed to address the short half-life and limited area for absorption of LD in the gastrointestinal tract. This paper presents the formulation strategy of IPX203 and its relationship to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	LeWitt, Peter, Ellenbogen, Aaron, Burdick, Daniel, Gunzler, Steven, Gil, Ramon, Dhall, Rohit, Banisadr, Ghazal, D'Souza, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172697/ https://www.ncbi.nlm.nih.gov/pubmed/37181100 http://dx.doi.org/10.1016/j.prdoa.2023.100197

Ejemplares similares

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
por: Morgan, John C., et al.
Publicado: (2018)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
por: Mao, Zhongping Lily, et al.
Publicado: (2016)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
por: Hauser, Robert A., et al.
Publicado: (2021)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials
por: Nausieda, Paul A., et al.
Publicado: (2015)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
por: Waters, Cheryl H., et al.
Publicado: (2015)

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Xanthonychia Due to Staining From Carbidopa-Levodopa
por: Hwang, Jonathan Kyle, et al.
Publicado: (2023)

Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation
por: Rosebraugh, Matthew, et al.
Publicado: (2019)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
por: Imbeah, Emelia Priscilla, et al.
Publicado: (2022)

Membranous nephropathy associated with the use of levodopa-carbidopa combination
por: Chaitanya, V., et al.
Publicado: (2015)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
por: Vijiaratnam, Nirosen, et al.
Publicado: (2017)

Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens
por: Thomson, Kate, et al.
Publicado: (2021)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
por: De Fabregues, Oriol, et al.
Publicado: (2017)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

The Clinical Development of Levodopa Inhalation Powder
por: Hauser, Robert A., et al.
Publicado: (2023)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

Proposition of zinc supplementation during levodopa–carbidopa intestinal gel treatment
por: Matsuyama, Hirofumi, et al.
Publicado: (2018)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0u7a6uvikubo155rnrrsqr2ien